市場調査レポート

商品コード

250301

代謝関連の各種提携契約：契約条件・合意内容

Global Metabolic Partnering 2014-2020: Deal trends, players and financials

出版日: 2021年09月01日 | 発行:

Current Partnering, a division of Wildwood Ventures Limited | ページ情報: 英文 700+ Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,495 401,365円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License - 2 to 5 Users)

USD 5,245 602,335円

レポートPDFを同一事業所（所在地）内の同一部署における2から5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Single Site License - 6+ Users)

USD 10,495 1,205,245円

レポートPDFを同一事業所（所在地）内の同一部署におけるすべての方にご利用頂けるライセンスです。ご利用人数の制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Global License)

USD 17,495 2,009,125円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=114.84円

担当者のコメント

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
目次

概要

サンプル依頼リストに入れる

当レポートでは、2007年以降の代謝関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章イントロダクション

第2章代謝関連の各種契約の動向

イントロダクション
過去数年における代謝関連の提携
大手製薬会社による契約活動
代謝関連の事業に積極的でない大手製薬会社
代謝関連の提携：契約タイプ別
代謝関連の提携：産業部門別
代謝関連の提携：開発ステージ別
代謝関連の提携：技術タイプ別
平均契約期間

第3章主要契約

イントロダクション
主要契約：取引額別
大手製薬会社のかかわる主要契約

第4章大手製薬会社による契約

イントロダクション
大手製薬会社による提携契約の利用法
企業プロファイル

第5章契約ディレクトリ

イントロダクション
契約タイプ別
- 資産購入
- 譲渡
- 大手によるアウトライセンシング
- 共同開発
- 共同R&D
- 共同販売
- サービス契約
- 共同プロモーション
- CRADA
- クロスライセンス
- 開発
- 流通
- 株式購入
- ライセンシング
- 訴訟
- ローン
- 製造
- マーケティング
- 材料転移
- オプション
- プロモーション
- 研究
- ロイヤルティ資金
- 和解関連
- スピンアウト
- サブライセンス
- 供給
- 技術移転
- 終了
開発ステージ別
- 創薬
- 製剤
- フェーズI
- フェーズII
- フェーズIII
- 前臨床
- 規制
- 製剤
技術タイプ別
- 解析
- 動物モデル
- アッセイ
- 生物学的化合物
- バイオマーカー
- バイオマテリアル
- 血液製剤
- 細胞培養
- 細胞治療
- 臨床検査
- デバイス
- 診断
- 創薬ツール
- DNAプローブ
- ドラッグデリバリー
- イネーブリング技術
- 設備
- 遺伝子治療
- ゲノミクス
- イメージング
- インプラント
- インビトロモデル
- マイクロアレイ
- ナノテクノロジー
- 天然製品
- オリゴヌクレオチド
- 希少薬
- パッケージング
- ペプチド
- 加工
- プロテオミクス
- 放射性/化学治療
- 組み換えDNA
- 再生医療
- 研究サービス
- 研究サプライ
- RNA治療
- スクリーニング
- 小分子
- 幹細胞
- 毒性
- ワクチン

第6章　代謝関連の契約：適応症別

代謝
末端肥大症
アジゾン病
肝硬変
クッシング症候群
糖尿病
脂肪肝
胆石
成長ホルモン疾患
甲状腺機能亢進症
性腺機能低下症
甲状腺機能低下症
フェニルケトン尿症
肝臓病
リソソーム蓄積症
栄養素・ビタミン
小人症
抗利尿ホルモン不適合分泌症候群(SIADH)
甲状腺疾患

第7章提携機会

オンラインパートナリング
パートナリングイベント
関連資料

付録

図表

Product Code: CP2205

Global Metabolic Partnering 2014-2021: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies

Global Metabolic Partnering 2014 to 2021 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Metabolic partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Metabolic partnering agreement structure

Metabolic partnering contract documents

Top Metabolic deals by value

Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

Global Metabolic Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

Global Metabolic Partnering 2014 to 2021 includes:

Trends in Metabolic dealmaking in the biopharma industry since 2014
Access to headline, upfront, milestone and royalty data
Access to hundreds of Metabolic deal contract documents
Comprehensive access to over 1100 Metabolic deal records
The leading Metabolic deals by value since 2014
Most active Metabolic dealmakers since 2014
The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In Global Metabolic Partnering 2014 to 2021, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Metabolic Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1100 metabolic deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Metabolic Partnering 2014 to 2021 provides the reader with the following key benefits:

In-depth understanding of Metabolic deal trends since 2014
Access Metabolic deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Metabolic partner companies
Comprehensive access to over 1100 links to actual Metabolic deals entered into by the world's biopharma companies
Indepth review of Metabolic deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Metabolic opportunities
Uncover companies actively partnering Metabolic opportunities